Monash IVF's Takeover Appeal Remains -- Market Talk

Dow Jones

01/14

2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. "We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time," analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

January 13, 2026 16:56 ET (21:56 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603536996"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603536996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603536996?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 05:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603536996","market":"sh","top_or_hot":-1,"title":"Monash IVF's Takeover Appeal Remains -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a>, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monash IVF's Takeover Appeal Remains -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonash IVF's Takeover Appeal Remains -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-14 05:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a>, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MVF.AU","symbol_name":"MONASH IVF GROUP LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603536996","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603536996","pubTimestamp":1768341360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MVF.AU":"MONASH IVF GROUP LTD","BK7113":"保健护理机构","IVF":"INVO Fertility, Inc","BK4082":"医疗保健设备","BK7508":"医药生物股"},"translate_title":"莫纳什IVF的收购吸引力依然存在——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVF":1.5,"MVF.AU":0.9},"content_text":"2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 16:56 ET (21:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}